Eli Lilly and Co., of Indianapolis, said the German Court of Appeal has ruled that the firm's vitamin regimen patent for Alimta (pemetrexed disodium) would not be infringed by a generic competitor that intends to market a dipotassium salt form of pemetrexed in Germany once the compound patent expires in December 2015.